Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John A Howe

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Marine Pollution Bulletin|July 12, 2017
Nuclear reprocessing-related radiocarbon (<sup>14</sup>C) uptake into UK marine mammalsKieran M Tierney, Graham K P Muir, Gordon T Cook, et al.
Antiviral Therapy|September 16, 2014
Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutationsAmanda L Aloia, Nicholas S Eyre, Stuart Black, et al.
Journal of Hepatology|March 5, 2013
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3Marcelo O Silva, Michelle Treitel, Donald J Graham, et al.
Cell Chemical Biology|April 25, 2017
Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch Disrupt Riboflavin Homeostasis in an Infectious SettingHao Wang, Paul A Mann, Li Xiao, et al.
Communications Biology|June 19, 2023
Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerasesVictoria A Kleiner, Thierry O Fischmann, John A Howe, et al.
Virology|July 24, 2013
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesRichard J O Barnard, John A Howe, Robert A Ogert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Nature|May 18, 2007
First insights into the biodiversity and biogeography of the Southern Ocean deep seaAngelika Brandt, Andrew J Gooday, Simone N Brandão, et al.
ACS Chemical Biology|February 8, 2018
Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass SpectrometryNoreen F Rizvi, John A Howe, Ali Nahvi, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Marine Pollution Bulletin|July 12, 2017
Nuclear reprocessing-related radiocarbon (<sup>14</sup>C) uptake into UK marine mammalsKieran M Tierney, Graham K P Muir, Gordon T Cook, et al.
Antiviral Therapy|September 16, 2014
Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutationsAmanda L Aloia, Nicholas S Eyre, Stuart Black, et al.
Journal of Hepatology|March 5, 2013
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3Marcelo O Silva, Michelle Treitel, Donald J Graham, et al.
Cell Chemical Biology|April 25, 2017
Dual-Targeting Small-Molecule Inhibitors of the Staphylococcus aureus FMN Riboswitch Disrupt Riboflavin Homeostasis in an Infectious SettingHao Wang, Paul A Mann, Li Xiao, et al.
Communications Biology|June 19, 2023
Conserved allosteric inhibitory site on the respiratory syncytial virus and human metapneumovirus RNA-dependent RNA polymerasesVictoria A Kleiner, Thierry O Fischmann, John A Howe, et al.
Virology|July 24, 2013
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studiesRichard J O Barnard, John A Howe, Robert A Ogert, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Nature|May 18, 2007
First insights into the biodiversity and biogeography of the Southern Ocean deep seaAngelika Brandt, Andrew J Gooday, Simone N Brandão, et al.
ACS Chemical Biology|February 8, 2018
Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass SpectrometryNoreen F Rizvi, John A Howe, Ali Nahvi, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Pageof 5